Organ protection by volatile anesthetics in non-coronary artery bypass grafting surgery

Future Cardiology

Volumn 5, Issue 6, 2009, Pages 589-603

  Landoni, Giovanni ^a   Turi, Stefano ^a   Bignami, Elena ^a   Zangrillo, Alberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cardiac anesthesia; Cardioprotection; Myocardial infarction; Preconditioning; Volatile anesthetics

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); ANESTHETIC AGENT; DESFLURANE; INHALATION ANESTHETIC AGENT; LEVOSIMENDAN; METOPROLOL; PLACEBO; PROPOFOL; REMIFENTANIL; SEVOFLURANE; TROPONIN I;

ABSENCE OF SIDE EFFECTS; AORTA SURGERY; AORTA VALVE REPLACEMENT; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG SAFETY; DRUG TISSUE LEVEL; HEART INFARCTION; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; LENGTH OF STAY; LOW DRUG DOSE; NONHUMAN; OFF PUMP CORONARY SURGERY; PERIOPERATIVE PERIOD; POSTOPERATIVE ANALGESIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; RISK REDUCTION; SURGICAL MORTALITY; SURGICAL RISK; VASCULAR SURGERY;

AMERICAN HEART ASSOCIATION; ANESTHETICS, INHALATION; CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; CORONARY ARTERY DISEASE; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; METHYL ETHERS; MYOCARDIUM; PRACTICE GUIDELINES AS TOPIC; STENTS; TREATMENT OUTCOME; UNITED STATES; VOLATILE ORGANIC COMPOUNDS;

EID: 74049117085     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.09.52     Document Type: Review

References (103)

1. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for non-cardiac surgery. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 50, 159-242 (2007). ■■ For the first time, the 2007 American College of Cardiology/American Heart Association guidelines for non-cardiac surgery suggested that it can be beneficial to use volatile anesthetic agents during non-cardiac surgery for the maintenance of general anesthesia in hemodynamically stable patients at risk for myocardial ischemia (class IIa, level of evidence B).
2. Weber NC, Schalck W: The concept of anesthetic-induced cardioprotection: mechanisms of action. Best Pract. Res. Clin. Anaesthesiol. 19, 429-443 (2005).
3. Landoni G, Bignami E, Fochi O, Zangrillo A: Halogenated anaesthetics and cardiac protection in cardiac and non-cardiac anaesthesia. Ann. Card. Anaesth. 12, 4-9 (2009).
4. Gupta A, Stierer T, Zuckerman R, Sakima N, Parker SD, Fleisher LA: Comparison of recovery profile after ambulatory anesthesia with propofol, isoflurane, sevoflurane and desflurane: a systematic review. Anesth. Analg. 98, 632-641 (2004).
5. Larsen B, Seitz A, Larsen R: Recovery of cognitive function after remifentanil-propofol anesthesia: a comparison with desflurane and sevoflurane anesthesia. Anesth. Analg. 90, 168-174 (2000).
6. Hwan SJ, Perk WJ: Sevoflurane versus propofol for anesthetic induction: a meta-analysis. Anesth. Analg. 91, 213-219 (2000).
7. Robinson BJ, Urich TD, Ebert TJ: A review of recovery from sevoflurane anesthesia: comparisons with isoflurane and propofol including meta-analysis. Acta Anesthesiol. Scand. 43, 185-190 (1999).
8. Sneyd JR, Carr A, Byrom WD, Bilski AJT: A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents. Eur. J. Anaesthesiol. 15, 433-445 (1998).
9. Fochi O, Landoni G, Bignami E et al.: Cardiac protection by volatile anaesthetics in non-cardiac surgery? A meta-analysis of randomized controller study on clinically relevant end-points. HSR Proc. (2009) (Epub ahead of print). ■ First and only meta-analysis that underlines how all the studies realized in non-cardiac surgery (and comparing a total intravenous anesthesia [TIVA] regimen versus an inhalational regimen) do not consider myocardial infarction or mortality as important variables.
10. Landoni G, Fochi O, Tritapepe L et al.: Cardiac protection by volatile anesthetics. A review. Minerva Anestesiol. 75, 269-273 (2009).
11. De Hert SG, Longrois D, Yang H, Fleisher LA: Does the use of a volatile anesthetic regimen attenuate the incidence of cardiac events after vascular surgery? Acta Anaesthesiol. Belg. 59, 19-25 (2008). ■ Authors studied a great number of patients (784 in total) in an important setting as the one of vascular surgery.
12. De Conno E, Steurer MP, Wittlinger M et al.: Anesthetic induced improvement of the inflammatory respones to one lung ventilation. Anesthesiol. 110, 1316-1326 (2009). ■ First randomized study that analyzes the cardioprotective effects of halogenated agents in a non-cardiac surgery setting.
13. Pasternack PF, Grossi EA, Baumann FG et al.: β-blockade to decrease silent myocardial ischemia during peripheral vascular surgery. Am. J. Surg. 158, 113-116 (1989).
14. Cucchiara RF, Benefiel DJ, Matteo RS, DeWood M, Albin MS: Evaluation of esmolol in controlling increases in heart rate and blood pressure during endotracheal intubation in patients undergoing carotidendarterectomy. Anesthesiol. 65, 528l-5231 (1986).
15. Landoni G, Fochi O, Bignami E, De Simone F, Zangrillo A: Volatile anesthetics for periprocedural cardiac protection. A review. Minerva Cardioangiol. 56, 429-434 (2008).
16. Landoni G, Fochi O, Zangrillo A: Cardioprotection by volatile anesthtics in noncardiac surgery? No, not yet at least. J. Am. Coll. Cardiol. 51, 1321 (2008).
17. Fleisher LA, Beckman JA, Brown KA et al.: ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 guidelines on perioperative cardiovascular evaluation for noncardiac surgery). J. Am. Coll. Cardiol. 50, 1707-1732 (2007).
18. Selvanayagam JB, Porto I, Channon K et al.: Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 111, 1027-1032 (2005).
19. Selvanayagam JB, Pigott D, Balacumaraswami L et al.: Relationship of irreversible myocardial injury to troponin I and creatine kinase-MB elevation after coronary artery bypass surgery:insights from cardiovascular magnetic resonance imaging. J. Am. Coll. Cardiol. 45, 629-631 (2005).
20. Giannitsis E, Muller-Bardorff M, Lehrke S et al.: Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 104, 630-635 (2001).
21. Landoni G, Zangrillo A, Fochi O et al.: Cardiac protection with volatile anesthetics in stenting procedures. J. Cardiothorac. Vasc. Anesth. 22, 543-547 (2008). ■■ First and only trial to investigate the effect of volatile anesthetics in patients undergoing interventional cardiology procedures.
22. De Hert SG, Van der Linden PJ, Cromheecke S: Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiol. 101, 299-310 (2004). ■■ Demonstrates for the first time how the cardioprotective effect achieved by halogenated agents correlates directly to the duration of its administration.
23. Bein B, Renner J, Caliebe D et al.: The effect of interrupted or continuous administration of sevoflurane on preconditioning before cardiopulmonary bypass in coronary artery surgery: comparison with continuous propofol. Anaesthesia 63 (10), 1046-1055 (2008).
24. Frabdorf J, Browski A, Ebel D et al.: Impact of preconditioning protocol on anesthetic induced cardioprotection in patients having coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 137 (6), 1436-1442 (2009).
25. Riess ML, Kevin LG, Camara AG et al.: Dual exposure to sevoflurane improves anesthetic preconditioning in intact hearts. Anesthesiol. 100 (3), 569-574 (2004).
26. 2-adrenergic receptors. J. Cardiothorac. Vasc. Anesth. 23 (5), 607-613 (2009). ■ Demonstrates how cardioprotection can be mediated by β-adrenergic signaling and that induced cardioprotection achieves a maximum that cannot be enhanced by further increments in the desflurane dose.
27. Landoni G, Biondi-Zoccai GGL, Zangrillo A et al.: Desflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. J. Cardiothorac. Vasc. Anesth. 21, 502-511 (2007). ■■ Demonstrates that desflurane and sevoflurane have cardioprotective effects that resulted in decreased morbidity and mortality in patients undergoing cardiac surgery.
28. Landoni G, Calabro MG, Marchetti C et al.: Desflurane versus propofol in patients undergoing mitral valve surgery. J. Cardiothorac. Vasc. Anesth. 21, 672-677 (2007). ■ First randomized study that analyzes the cardioprotection by volatile agents in mitral valve surgery.
29. Goldfine H, Aurigemma GP, Zile MR et al.: Left ventricular length-force-shortening relations before and after surgical correction of chronic mitral regurgitation. J. Am. Coll. Cardiol. 31, 180-185 (1998).
30. Cromheecke S, Pepermans V, Hendrickx E et al.: Cardioprotective properties of sevoflurane in patients undergoing aortic valve replacement with cardiopulmonary bypass. Anesth. Analg. 103, 289-296 (2006). ■ First randomized study that analyzes the cardioprotection by volatile agents in aortic valve surgery.
31. Lehrke S, Steen H, Sievers HH et al.: Cardiac troponin T for prediction of short-and long-term morbidity and mortality after elective open heart surgery. Clin. Chem. 50, 1560-1567 (2004).
32. Symons JA, Myles PS: Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. Br. J. Anaesth. 97, 127-136 (2006).
33. Yu CH, Beattie WS: The effects of volatile anesthetics on cardiac ischemic complications and mortality in CABG: a meta-analysis. Can. J. Anaesth. 53, 906-918 (2006).
34. Preckel B, Bolten J: Pharmacology of modern volatile anaesthetics. Best Pract. Res. Clin. Anaesthesiol. 19, 331-348 (2005).
35. Hartman JC, Pagel PS, Proctor LT et al.: Influence of desflurane, isoflurane and halothane on regional tissue perfusion in dogs. Can. J. Anaesth. 39, 877-887 (1992).
36. De Hert SG, Van der Linden PJ, Cromheecke S et al.: Choice of primary anesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass. Anesthesiol. 101, 9-20 (2004). ■ Demonstrates that patients undergoing coronary surgery under cardio-pulmonary bypass had a lower postoperative troponin, improved left ventricular function and shorter stay in the intensive care unit when they received sevoflurane or desflurane compared with an intravenous protocol. This is a randomized trial realized on a large number population (320 patients).
37. Tritapepe L, Landoni G, Guarracino F et al.: Cardiac protection by desflurane. A multicenter randomized controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Eur. J. Anaesthesiol. 24, 323-331 (2007). ■ First multicenter, randomized study that analyzes the cardioprotection by volatile agents in coronary artery bypass grafting (CABG) surgery.
38. Guarracino F, Landoni G, Tritapepe L et al.: Myocardial damage prevented by volatile anesthetics. A multicentre randomized controlled study. J. Cardiothorac. Vasc. Anesth. 20, 477-483 (2006). ■ First multicenter, randomized study that analyzes the cardioprotection by volatile agents in off-pump coronary artery bypass (OPCAB) surgery.
39. Murphy GJ, Ascione R, Angelini GD: Coronary artery bypass grafting on the beating heart: surgical revascularization for the next decade? Eur. Heart. J. 25, 2077-2085 (2004).
40. Cheng DC, Bainbridge D, Martin JE et al.; Evidence-Based Perioperative Clinical Outcomes Research Group: Does off-pump coronary artery bypass reduce mortality, morbidity, and resource utilization when compared with conventional coronary artery bypass? A meta-analysis of randomized trials. Anesthesiol. 102, 188-203 (2005).
41. Jordan JE, Zhao ZQ, Vinten-Johansen J: The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc. Res. 43, 860-878 (1999).
42. Seccareccia F, Perucci CA, D'Errigo P et al.: The Italian CABG Outcome Study: short-term outcomes in patients with coronary artery bypass graft surgery. Eur. J. Cardiothorac. Surg. 29, 56-62 (2006).
43. Bignami E, Biondi-Zoccai G, Landoni G et al.: Volatile anesthetics reduce mortality in cardiac surgery. Cardiothorac. Vasc. Anesth. 23 (5), 594-599 (2009). ■■ Presents a survey conducted among Italian centers (64 hospitals for 34, 310 patients) that indicates how the use of halogenated agents is associated with a reduction of mortality in cardiac surgery.
44. Jakobsen CJ, Berg H, Hindsholm KB, Faddy N, Sloth E: The influence of propofol versus sevoflurane anesthesia on outcome in 10, 535 cardiac surgical procedures. J. Cardiothorac. Vasc. Anesth. 21, 664-671 (2007). ■■ Studied 10, 000 patients in a retrospective study.
45. Smul TM, Redel A, Stumpner J et al.: Time course of desflurane-induced preconditioning in rabbits. J. Cardiothorac. Vasc. Anesth. DOI: 10.1053/j.jvca.2009. 03.006 (2009) (Epub ahead of print). ■■ Analyzes the molecular mechanisms underlying anesthetic preconditioning and the possible role of nitric oxide.
46. Obal D, Preckel B, Scharbatke H et al.: One MAC of sevoflurane provides protection against reperfusion injury in the rat heart in vivo. Br. J. Anaesth. 87, 905-911 (2001).
47. Obal D, Scharbatke H, Barthel H et al.: Cardioprotection against reperfusion injury is maximal with only two minutes of sevoflurane administration in rats. Can. J. Anaesth. 50, 940-945 (2003).
48. Chiari PC, Bienengraeber MW, Pagel PS et al.: Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits. Anesthesiol. 102, 102-109 (2005).
49. Feng J, Lucchinetti E, Ahuja P et al.: Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3β. Anesthesiol. 103, 987-995 (2005).
50. Preckel B, Schlack W, Comfere T et al.: Effects of enflurane, isoflurane, sevoflurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo. Br. J. Anaesth. 81, 905-912 (1998).
51. Dawn B, Bolli R: Role of nitric oxide in myocardial preconditioning. Ann. NY Acad. Sci. 962, 18-41 (2002).
52. Kersten JR, Schmeling TJ, Hettrick DA et al.: Mechanism of myocardial protection by isoflurane. Role of adenosine triphosphate regulated potassium (KATP) channels. Anesthesiol. 85, 794-807 (1996).
53. Krolikowski JG, Bienengraeber M, Weihrauch D et al.: Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial KATP channels. Anesth. Analg. 101, 1590-1596 (2005).
54. Obal D, Dettwiler S, Favoccia C et al.: The influence of mitochondrial KATP-channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo. Anesth. Analg. 101, 1252-1260 (2005).
55. Bell RM, Maddock HL, Yellon DM: The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart. Cardiovasc. Res. 57, 405-415 (2003).
56. Sasaki N, Sato T, Ohler A et al.: Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 101, 439-445 (2000).
57. Smul TM, Lange M, Redel A et al.: Desflurane induced cardioprotection against ischemia reperfusion injury depends on timing. J. Cardiothorac. Vasc. Anesth. (2009) (Epub ahead of print).
58. Haelewyn B, Zhu L, Hanouz JL et al.: Cardioprotective effects of desflurane: effect of timing and duration of administration in rat myocardium. Br. J. Anaesth. 92, 552-557 (2004).
59. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74, 1124-1136 (1986).
60. Bolling SF, Olszanski DA, Childs KF, Gallagher KP, Ning XH: Stunning, preconditioning and functional recovery after global myocardial ischemia. Ann. Thorac. Surg. 58, 822-827 (1994).
61. SchlackW, Hollmann M, Stunneck J, Thamer V: Effect of halothane on myocardial reoxygenation injury in the isolated rat heart. Br. J. Anaesth. 76, 860-867 (1996).
62. Siegmund B, Schlack W, Ladilov YV et al.: Halothane protects cardiomyocytes against reoxygenationinduced hypercontracture. Circulation 96, 4372-4379 (1997).
63. De Hert SG: The concept of anaestheticinduced cardioprotection: clinical relevance. Best Pract. Res. Clin. Anaesthesiol. 19, 445-459 (2005). ■ Interesting review article analyzing in detail the cardioprotection by volatile agents.
64. De Hert SG, Turani F, Mathur S, Stowe DF: Cardioprotection with volatile anesthetics: mechanisms and clinical implications. Anaesth. Analg. 100, 1584-1593 (2005).
65. Warltier DC, Pagel PS, Kersten JR: Approaches to the prevention of perioperative myocardial ischemia. Anesthesiol. 92, 253-259 (2000).
66. Warltier D, Al-Wathiqui M, Kampine J, Schmelling W: Recovery of contractile function of stunned myocardium in chronically instrumented dogs is enhanced by halothane or isoflurane. Anesthesiol. 69, 552-565 (1988).
67. Kersten JR, Brayer AP, Pagel PS et al.: Perfusion of ischemic myocardium during anesthesia with sevoflurane. Anesthesiol. 81, 995-1004 (1994).
68. Liu R, Ishibe Y, Ueda M: Isofluranesevoflurane administration before ischemia attenuates ischemia-reperfusion-induced injury in isolated rat lungs. Anesthesiol. 92, 833-840 (2000).
69. Piriou V, Chiari P, Lhuillier F et al.: Pharmacological preconditioning: comparison of desflurane, sevoflurane, isoflurane and halothane in rabbit myocardium. Br. J. Anaesth. 89, 486-491 (2002).
70. Ross S, Foëx P: Protective effects of anaesthetics in reversible and irreversible ischaemia-reperfusion injury. Br. J. Anaesth. 82, 622-632 (1999).
71. Kitakaze M, Hori M, Morioka T et al.: Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 50-nucleotidase activity and attenuation of adenosine release. Circulation 89, 1237-1246 (1994).
72. Tsuchida A, Liu Y, Liu GS et al.: α1-adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ. Res. 75, 576-585 (1994).
73. Yao Z, Gross GJ: Acetylcholine mimics ischemic preconditioning via a glibenclamidesensitive mechanism in dogs. Am. J. Physiol. 264, 2221-2225 (1993).
74. Zaugg M, Lucchinetti E, Spahn DR et al.: Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial KATP channels via multiple signalling pathways. Anesthesiol. 9 7, 4-14 (2002).
75. O'Rourke B: Myocardial KATP channels in preconditioning. Circ. Res. 87, 845-855 (2000).
76. Liu Y, Sato T, Seharaseyon J, Szewczyk A, O'Rourke B, Marbán E: Mitochondrial ATP-dependent potassium channels: viable candidate effectors of ischemic preconditioning. Ann. NY Acad. Sci. 874, 27-37 (1999).
77. Kowaltowski AJ, Seetharaman S, Paucek P, Garlid KD: Bioenergetic consequences of opening the ATP-sensitive K-channel of heart mitochondria. Am. J. Physiol. 280, H649-H657 (2001).
78. Sergeev P, Da Silva R, Lucchinetti E et al.: Trigger dependent gene-expression profiles in cardiac pre-conditioning: evidence for distinctive genetic programs in ischemic and anesthtetic pre-conditioning. Anesthesiol. 100 (3), 474-478 (2004).
79. Weber NC, Toma O, Awan S et al.: Effects of the nitrous oxide on the heart rat in vivo: another inhalational anesthetic that preconditions the heart? Anesthesiol. 103, 1174-1182 (2005).
80. Weber NC, Preckel B, Schlack W: The effects of anaesthetics on the myocardium-new insights into myocardial protection. Eur. J. Anaesthesiol. 22, 647-657 (2005).
81. Novalija E, Fujita S, Kampine JP, Stowe DF: Sevoflurane mimics ischemic preconditioning effects on coronary flow and nitric oxide release in isolated hearts. Anesthesiol. 91, 701-712 (1999).
82. Weber NC, Schlack W: Inhalational anaesthetics and cardioprotection. Handb. Exp. Pharmacol. 182, 187-207 (2008).
83. Landoni G, Zambon M, Zangrilo A: Reducing perioperative myocardial infarction with drugs and techniques. Curr. Drug Targets 10 (9), 858-862 (2009). ■ Interesting review article analyzing in detail the drugs and the techniques used to reduce perioperative myocardial infarction.
84. Landoni G, Mizzi A, Biondi-Zoccai G et al.: Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. J. Cardiothorac. Vasc. Anesth. (2009) (Epub ahead of print).
85. Zangrillo A, Biondi-Zoccai GG, Mizzi A et al.: Levosimendan reduces cardiac troponin release after cardiac surgery. A meta-analysis of randomized controlled studies. J. Cardiothorac. Vasc. Anesth. 23 (4), 474-478 (2009).
86. Wijeysundera DN, Beattie WS, Austin PC, Hux JA, Lupacis A: Epidural anaesthesia and survival after intermediate-to-high risk non-cardiac surgery: a population-based cohort study. Lancet 16 (372), 562-569 (2008).
87. Rigg JR, Jamrozik K, Myles PS, Sylbert BS, Peyton PJ: Epidural anaesthesia and analgesia and outcome of mayor surgery: a randomised trial. Lancet 359, 1276-1282 (2002).
88. Crescenzi G, Landoni G, Monaco F et al.: Epidural anesthesia in elderly patients undergoing coronary artery bypass graft surgery. J. Cardiothorac. Vasc. Anesth. (2009) (Epub ahead of print).
89. Landoni G: Epidural anesthesia and analgesia in cardiac surgery. Minerva Anestesiol. 74, 617-618 (2008).
90. Badner NH, Knell RL, Brawn JE et al.: Myocardial infarction after non-cardiac suregry. Anesthesiol. 88 (3), 572-578 (1998).
91. Devereaux PJ, Yang H, Yusuf S et al.; POISE Study Group: Effects of extended release metoprolol succinate in Patients Undergoing Non-cardiac Surgery (POISE trial) : a randomised controlled trial. Lancet 371, 1839-1847 (2008).
92. De Hert SG: Anesthetic preconditioning: how important is it in today's cardiac anesthesia? J. Cardiothorac. Vasc. Anesth. 20, 473-476 (2003).
93. Landoni G, Fochi O, Torri G: Cardiac protection by volatile anesthetics: a review. Curr. Vasc. Pharmacol. 6, 108-111 (2008).
94. Sessler CN, Varney K: Patient focused sedation and analgesia in the ICU. Chest 133, 552-565 (2008).
95. Jacobi J, Fraser GL, Coursin DB et al.: Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit. Care Med. 30, 119-141 (2002).
96. Ostermann ME, Keenan SP, Seiferling RA, Sibbald WJ: Sedation in the intensive care unit: a systematic review. JAMA 283, 1451-1459 (2000).
97. Enlund M, Wiklund L, Lambert H: A new device to reduce the consumption of a halogenated anaesthetic agent. Anaesthesia 56, 429-432 (2001).
98. Sackey PV, Martling CR, Granath F, Radell PJ: Prolonged isoflurane sedation of intensive care unit patients with the Anesthetic Conserving Device. Crit. Care Med. 32, 2241-2246 (2004).
99. Migliari M, Bellani G, Rona R et al.: Short-term evaluation of sedation with sevoflurane administered by the anesthetic conserving device in critically ill patients. Intensive Care Med. 35, 1240-1246 (2009).
100. Behne M, Wilke HJ, Harder S: Clinical pharmacokinetics of sevoflurane. Clin. Pharmacokinet. 36, 13-26 (1999).
101. Belda JF, Soro M, Badenes R et al.: The predictive performance of a pharmacokineticmodel for manually adjusted infusion of liquid sevofluorane for use with the Anesthetic Conserving Device (AnaConDa) : a clinical study. Anesth. Analg. 106, 1207-1214 (2008).
102. Rohm KD, Mengistu A, Boldt J et al.: Renal integrity in sevoflurane sedation in the intensive care unit with the anesthetic conserving device : a comparison with intravenous propofol sedation. Anesth. Analg. 108 (6), 1848-1854 (2006).
103. Soukup J, Schärff K, Kubosch K, Rudzki M, Zielonka M, Radke J: Sedation with volatile anaesthetics in ICU: technical performance and current experience (German). Intensiv-und Notfallbehandlung 32, 29-36 (2007).